Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cathay BiotechSHSE:688065 -0.02%92 Net Margin % is 18.95% as of Mar. 2026, which is 19% below its 10-year median of 23.54. GuruFocus rates SHSE:688065 with a GF Score™ of 92/100 and a GF Value™ of ¥50.12 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 1,579 Chemicals companies, Cathay Biotech ranks better than 92.08% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Cathay Biotech's Net Income for the
three
months ended in Mar. 2026 was ¥166 Mil. Cathay Biotech's Revenue for the
three
months ended in Mar. 2026 was ¥875 Mil. Therefore, Cathay Biotech's net margin for the quarter that ended in Mar. 2026 was 18.95%.
The historical rank and industry rank for Cathay Biotech's Net Margin % or its related term are showing as below:
SHSE:688065'
s Net Margin % Range Over the Past 10 Years
Min: 15.66 Med: 23.54 Max: 30.57
Current: 17.37
SHSE:688065's Net Margin % is ranked better than 92.08% of 1579
companies
in the Chemicals industry
Industry Median: 3.92
vs SHSE:688065: 17.37
Cathay Biotech (SHSE:688065) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Cathay Biotech Net Margin % Related Terms
Cathay Biotech Net Margin % Historical Data
* Premium members only.
The historical data trend for Cathay Biotech's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Chemicals subindustry, Cathay Biotech's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cathay Biotech Net Margin % vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Cathay Biotech's Net Margin % distribution charts can be found below:
* The bar in red indicates where Cathay Biotech's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cathay Biotech (SHSE:688065) has a Net Margin % of 18.95% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Cathay Biotech and its competitors. This is 19% below median its historical median of 23.54. Over the past decade, Cathay Biotech's Net Margin % has ranged from 15.66 to 30.57. According to the industry distribution chart, Cathay Biotech ranks #125 out of 1579 companies in the Chemicals industry, placing it in the top 7.9%.
Is Cathay Biotech's Net Margin % too high?
Cathay Biotech's current Net Margin % of 18.95% is 19% below median its 10-year median of 23.54. Over the past 10 years, this metric has ranged from a low of 15.66 to a high of 30.57. The Chemicals industry median Net Margin % is 3.92. Cathay Biotech's value of 18.95% is 383.4% above this industry median. Based on the distribution chart, Cathay Biotech ranks #125 out of 1579 companies in the Chemicals industry, which is in the top quartile — a strong position relative to peers. Overall, Cathay Biotech has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cathay Biotech's Net Margin % compare to DOW?
According to the Chemicals industry distribution chart, Cathay Biotech ranks #125 out of 1579 companies for Net Margin %. This places Cathay Biotech in the top 8% of its industry — outperforming the majority of peers. The industry median Net Margin % is 3.92. Cathay Biotech's value of 18.95% is 383.4% above this benchmark. Historically, Cathay Biotech's own Net Margin % has ranged from 15.66 to 30.57 over the past decade. While the company's 10-year median is 23.54 vs. the industry median of 3.92, Cathay Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Chemicals company?
The median Net Margin % among Chemicals companies is 3.92, based on 1,579 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cathay Biotech's current Net Margin % of 18.95% is 383.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Cathay Biotech and its competitors. For the Chemicals industry, the median Net Margin % is 3.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cathay Biotech's current Net Margin % is 18.95%, which is 19% below median its own 10-year median of 23.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cathay Biotech stock overvalued right now?
Based on GuruFocus' analysis, Cathay Biotech (SHSE:688065) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥50.12, compared to a current price of ¥42.75 — trading 14.7% below its estimated fair value. The current Net Margin % is 18.95%, which is 19% below median its 10-year median of 23.54 and 383.4% above the Chemicals industry median of 3.92. Cathay Biotech's overall GF Score™ is 92/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Cathay Biotech (SHSE:688065), the current Net Margin % is 18.95% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cathay Biotech (SHSE:688065) Overvalued in 2026?
Based on GuruFocus' analysis, Cathay Biotech stock appears to be undervalued.
The current stock price of ¥42.75 is trading 14.7% below its estimated GF Value™ of ¥50.12.
GuruFocus considers Cathay Biotech to be Modestly Undervalued.
Key valuation signals for SHSE:688065:
Net Margin %: 18.95% (19% below median its 10-year median of 23.54)
GF Value™: ¥50.12 vs. price of ¥42.75 (14.7% below fair value)
Industry Position: 383.4% above the Chemicals median (#125 of 1579)
No single metric tells the full story. See the SHSE:688065 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cathay Biotech Inc is engaged in research, development, production, and sales of new bio-based materials. The company owns the TERRYL brand, which focuses on bio-based polyamide fibers for textiles, and ECOPENT, which serves the engineering materials market.
92GF Score
Get the complete analysis for SHSE:688065
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688065 has been successfully added to your 
